

	Indication/Target	Program	Preclinical	Phase 1	Phase 2	Phase 3	Trial Name / Collaborator
Late stage	NSCLC (2 nd /3 rd line)	Plinabulin + Docetaxel					DUBLIN-3
	CIN Prevention	Plinabulin + Pegfilgrastim					PROTECTIVE-1 & PROTECTIVE-2
Investigator Initiated Trials	SCLC (2 nd /3 rd line PD-1/PD-L1 failed)	Plinabulin + PD-1 + CTLA-4					Bristol Myers Squibb RUTGERS
	NSCLC (2 nd /3 rd line PD-1 failed)	Plinabulin + PD-1 + Docetaxel					MERCK
	7 cancers (PD-1/PD-L1 failed)	Plinabulin + PD-1/PD-L1 + Radiation					THE UNIVERSITY OF TEXAS MDAnderson Cancer Center
	AHCT (hematopoietic stem cell transplantation) in Multiple myeloma	Plinabulin + Pegfilgrastim					Memorial Sloan Kettering Cancer Center
Early Stage	Preclinical assets	BPI-002, BPI-003, BPI-004					
SEED Therapeutics	KRAS and additional targets	Targeted Protein Degradation (TPD) Molecule Glue Platform					SEED THERAPEUTICS
	Multiple	TPD (Molecular Glue)					Lilly